Spark completes FDA application for gene therapy candidate to repair vision loss
Spark Therapeutics said Thursday it has completed its rolling submission of its biologics license application for its lead gene therapy candidate, voretigene neparvovec, with the Food and Drug Administration.
If approved, voretigene neparvovec is in position to become the first gene therapy in the United States for a genetic disease.
Spark (NASDAQ: ONCE), a company spun out of Children’s Hospital of Philadelphia, is developing the gene therapy as a one-time treatment for patients with vision…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: John George Source Type: news
More News: Eyes | Food and Drug Administration (FDA) | Gastroschisis Repair | Gene Therapy | Genetics | Health Management | Hospitals | Pharmaceuticals